These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30535958)

  • 1. Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model.
    Secombe KR; Ball IA; Shirren J; Wignall AD; Finnie J; Keefe D; Avogadri-Connors F; Olek E; Martin D; Moran S; Bowen JM
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):531-543. PubMed ID: 30535958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
    Secombe KR; Ball IA; Shirren J; Wignall AD; Keefe DM; Bowen JM
    Breast Cancer; 2021 Jan; 28(1):99-109. PubMed ID: 32683606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
    Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.
    Secombe KR; Ball IA; Wignall AD; Bateman E; Keefe DM; Bowen JM
    Neoplasia; 2022 Aug; 30():100806. PubMed ID: 35561424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib-induced diarrhea in HER2-positive breast cancer-A pilot study.
    Bowen J; Braga S; Zotto VD; Finnie J; DiPrimeo D; Cooke B; Bischof GF; Wong A; Di Palma JA
    Physiol Rep; 2024 Aug; 12(16):e70008. PubMed ID: 39187401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.
    Abbas R; Hug BA; Leister C; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):191-9. PubMed ID: 22418773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
    Chan A; Ruiz-Borrego M; Marx G; Chien AJ; Rugo HS; Brufsky A; Thirlwell M; Trudeau M; Bose R; García-Sáenz JA; Egle D; Pistilli B; Wassermann J; Cheong KA; Schnappauf B; Semsek D; Singer CF; Foruzan N; DiPrimeo D; McCulloch L; Hurvitz SA; Barcenas CH
    Breast; 2023 Feb; 67():94-101. PubMed ID: 36702070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.
    Lysyy T; Lalani AS; Olek EA; Diala I; Geibel JP
    Pharmacol Res Perspect; 2019 Oct; 7(5):e00521. PubMed ID: 31523434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
    Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
    Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
    Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
    Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
    J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
    Jacob S; Johnson M; Roque B; Quintal L; Rugo HS; Melisko M; Chien AJ
    Clin Breast Cancer; 2023 Oct; 23(7):721-728. PubMed ID: 37474374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
    Van Sebille YZA; Gibson RJ; Wardill HR; Secombe KR; Ball IA; Keefe DMK; Finnie JW; Bowen JM
    Int J Cancer; 2017 Jun; 140(12):2820-2829. PubMed ID: 28316082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
    Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
    J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.
    Guy M; Teixeira A; Shrier A; Meschter C; Bolognese J; Chaturvedi P
    PLoS One; 2024; 19(1):e0282769. PubMed ID: 38265977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferroptosis - a potential feature underlying neratinib-induced colonic epithelial injury.
    Nguyen TPM; Woods SL; Secombe KR; Tang S; Elz AS; Ayton S; Finnie J; Nagpal A; Pouliot N; Bowen JM
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):493-505. PubMed ID: 39002022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.